ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
DISCOVERY
From novel biology to clinical stage products.
Rich Pipeline
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Experienced team
Our team brings success from biotech pharma, and academia to OncoC4.
ONC-781, 782, 783, and 784
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
Exploring Our Pipeline:
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Rising To The Most Pressing Challenge In Immunotherapy
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
YANG LIU, PHD
CHIEF EXECUTIVE OFFICER & CHIEF SCIENTIFIC OFFICER
Latest News
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications The randomized Phase 3 trial is expected to enroll approximately 600 patients with…
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual…
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial planned to start in 2023 BioNTech also plans…